Danaparoid—Consensus Recommendations on Its Clinical Use
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/12/1584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850085053320658944 |
|---|---|
| author | Rupert M. Bauersachs Edelgard Lindhoff-Last Robert Klamroth Andreas Koster Marc Schindewolf Harry Magnani |
| author_facet | Rupert M. Bauersachs Edelgard Lindhoff-Last Robert Klamroth Andreas Koster Marc Schindewolf Harry Magnani |
| author_sort | Rupert M. Bauersachs |
| collection | DOAJ |
| description | (1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations. (3) Results: Dosing regimens are proposed, together with monitoring recommendations and target anti-factor Xa ranges. (4) Conclusion: In a comprehensive summary detailed interdisciplinary dosing recommendations are described to provide a basis for safe and effective use of danaparoid. |
| format | Article |
| id | doaj-art-5723ccd55eaa4c48b9bd8d02ffb952ad |
| institution | DOAJ |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-5723ccd55eaa4c48b9bd8d02ffb952ad2025-08-20T02:43:49ZengMDPI AGPharmaceuticals1424-82472024-11-011712158410.3390/ph17121584Danaparoid—Consensus Recommendations on Its Clinical UseRupert M. Bauersachs0Edelgard Lindhoff-Last1Robert Klamroth2Andreas Koster3Marc Schindewolf4Harry Magnani5Cardioangiology Center Bethanien, Vascular Center and Coagulation Center, Im Prüfling 23, 60389 Frankfurt, GermanyCardioangiology Center Bethanien, Vascular Center and Coagulation Center, Im Prüfling 23, 60389 Frankfurt, GermanyDepartment Angiology and Haemostaseology, Vivantes Klinikum Friedrichsheim, Landsberger Allee 49, Friedrichshain, 10249 Berlin, GermanyDepartment of Cardio-Anaesthesiology, Sana-Herzzentrum Cottbus GmbH, Leipziger Straße 50, 03048 Cottbus, GermanyDivision of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, SwitzerlandIndependent Researcher, 5345 MT Oss, The Netherlands(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations. (3) Results: Dosing regimens are proposed, together with monitoring recommendations and target anti-factor Xa ranges. (4) Conclusion: In a comprehensive summary detailed interdisciplinary dosing recommendations are described to provide a basis for safe and effective use of danaparoid.https://www.mdpi.com/1424-8247/17/12/1584Orgarandanaparoidheparinoidanticoagulantdosingmonitoring |
| spellingShingle | Rupert M. Bauersachs Edelgard Lindhoff-Last Robert Klamroth Andreas Koster Marc Schindewolf Harry Magnani Danaparoid—Consensus Recommendations on Its Clinical Use Pharmaceuticals Orgaran danaparoid heparinoid anticoagulant dosing monitoring |
| title | Danaparoid—Consensus Recommendations on Its Clinical Use |
| title_full | Danaparoid—Consensus Recommendations on Its Clinical Use |
| title_fullStr | Danaparoid—Consensus Recommendations on Its Clinical Use |
| title_full_unstemmed | Danaparoid—Consensus Recommendations on Its Clinical Use |
| title_short | Danaparoid—Consensus Recommendations on Its Clinical Use |
| title_sort | danaparoid consensus recommendations on its clinical use |
| topic | Orgaran danaparoid heparinoid anticoagulant dosing monitoring |
| url | https://www.mdpi.com/1424-8247/17/12/1584 |
| work_keys_str_mv | AT rupertmbauersachs danaparoidconsensusrecommendationsonitsclinicaluse AT edelgardlindhofflast danaparoidconsensusrecommendationsonitsclinicaluse AT robertklamroth danaparoidconsensusrecommendationsonitsclinicaluse AT andreaskoster danaparoidconsensusrecommendationsonitsclinicaluse AT marcschindewolf danaparoidconsensusrecommendationsonitsclinicaluse AT harrymagnani danaparoidconsensusrecommendationsonitsclinicaluse |